Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

BMP adds cost to spinal fusion: Application of bone-morphogenetic protein (BMP) in anterior cervical spinal fusions increases the likelihood of complications and increases the cost of all types of spinal fusions, according to results of a retrospective cohort study of 328,468 patients in the Nationwide Inpatient Sample database appearing in the July 1 Journal of the American Medical Association. The study found that BMP was used in about 25% of all spinal fusions in the United States in 2006, including 56% of the procedures in women and 30% of procedures in Medicare patients, but in only about 9% of non-white patients. In the study, BMP in anterior cervical fusion increased the risk of complications, including wound complications, from about 4.7% to 7%, while adding 11% to 41% to total hospital charges for all types of spinal fusion. Study authors Kevin S. Cahill, M.D./Ph.D., Brigham and Women's Hospital, Boston, et al. write that the results "illustrate the need to continue to develop refined guidelines for [BMP] and to further study the long-term risks and benefits of [BMP]." This is the first nationwide survey of on-label and off-label BMP applications in spinal fusion, according to the authors. FDA first approved BMP in 2002 when it approved Medtronic's Infuse bone graft to be used with the LT-Cage lumbar tapered fusion device. Stryker's OP-1 BMP putty is approved as a humanitarian use device for revision of inter-transverse lumbar fusion in compromised patients

You may also be interested in...

Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar

On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.

Everlywell Raises $175M To Expand Consumer Lab Testing, Digital Health

The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.

UK Faces Distribution Challenges With Pfizer/BioNTech Vaccine

New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts